Explore

Trendline Trendline
Amgen Advances Thyroid Eye Disease Treatment with New Formulation

Amgen Advances Thyroid Eye Disease Treatment with New Formulation

Amgen Advances Thyroid Eye Disease Treatment with New Formulation
Trendline Trendline
Amgen's New Tepezza Formulation Aims to Boost Sales Amidst Market Challenges

Amgen's New Tepezza Formulation Aims to Boost Sales Amidst Market Challenges

Amgen's New Tepezza Formulation Aims to Boost Sales Amidst Market Challenges
Trendline Trendline
API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development
Trendline Trendline
Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment
Trendline Trendline
API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'
Trendline Trendline
FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls
Trendline Trendline
Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial

Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial

Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial
Trendline Trendline
Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Dermatology Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Dermatology Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Dermatology Conditions
Trendline Trendline
Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions
Trendline Trendline
Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus
Trendline Trendline
Eli Lilly's Foundayo Pill Approved by FDA, Offers New Weight Loss Option

Eli Lilly's Foundayo Pill Approved by FDA, Offers New Weight Loss Option

Eli Lilly's Foundayo Pill Approved by FDA, Offers New Weight Loss Option
Trendline Trendline
Viking and Structure Therapeutics Become Key Targets in Metabolic Health Sector

Viking and Structure Therapeutics Become Key Targets in Metabolic Health Sector

Viking and Structure Therapeutics Become Key Targets in Metabolic Health Sector